Archives duchenne-muscular-dystrophy

by in
Entry Author Date Location
East Coast Biotech Roundup: HART, CoStim, Forest/Actavis, & More 02/21/14 Boston
East Coast Biotech Roundup: Enanta, NY Disruptors, Repligen, & More 01/24/14 Boston
East Coast Biotech Roundup: JP Morgan Edition 01/17/14 Boston
East Coast Biotech Roundup: Sarepta, Zalicus, Alkermes, & More 11/15/13 Boston
In Defense of Sarepta’s Chris Garabedian 11/14/13 National
Sarepta Shares Crumble As FDA Calls New Drug Application “Premature” 11/12/13 Boston
East Coast Life Sciences Roundup: Foundation, Ophthotech, Sato, & More 09/27/13 Boston
East Coast Life Sciences Roundup: Sarepta, Agios, Gerngross, & (Much) More 07/26/13 Boston
The Biotech IPO Phenomenon of 2013: Enjoy It While It Lasts 07/22/13 National
East Coast Life Sciences Roundup: Alkermes, Ensemble, Sinai, & More 07/19/13 Boston
NIH Award Will Help Phrixus Pharmaceuticals Advance to Clinical Trials 07/10/13 Detroit Ann Arbor
East Coast Life Sciences Roundup: IPO Madness, Amicus, & More 06/21/13 Boston
PTC Therapeutics IPO Raises $125M Despite Checkered Past 06/20/13 New York
Profiles in Long-Termism: Sarepta Therapeutics CEO Chris Garabedian 06/10/13 National
East Coast Life Sciences Roundup: ASCO, Follica, Aveo, & More 06/07/13 Boston
Henri Termeer on Startups, Drug Prices, Getting Older (Part 1) 05/13/13 National
East Coast Biotech Roundup: Biogen Idec, Third Rock, T2 Bio, Dart 03/29/13 Boston
Foundation-Backed Dart Revs Up, Seeks Venture Funds 03/29/13 Boston
Sarepta Announces Price of $125 Million Stock Offering 12/14/12 Boston
Sarepta Moves From Seattle to Boston for the Talent 09/07/12 Seattle
Sarepta Holds Its Breath as Feds Order Halt to Ebola Work 08/07/12 Seattle
Halo Gathers $1.1M From Patient Groups for Muscular Dystrophy Drug 05/24/12 Boston
Retrophin, Headed by Controversial Hedge Fund Chief, Raises $4M 05/07/12 New York
N-Gene Digs Up Funds to Boost “Heat Shock” Drug in Diabetes and MD 04/25/12 New York
AVI Biopharma Mulls Deal After Mixed Data With Muscular Dystrophy Drug 04/06/12 Seattle
Hard-Nosed Hedge Fund Chief Has Soft Spot for Rare-Disease Startup 04/03/12 New York
AVI Biopharma Passes Small Study in Muscular Dystrophy 04/02/12 Seattle
AVI Biopharma Axes 28% of Workforce, After Missing Out on Flu Contract 12/12/11 Seattle
AVI Biopharma CEO Chris Garabedian Seeks to Avoid Quick Flip, Build Enduring Drug Company 06/02/11 Seattle
Shire Finds Big Value in Rare Diseases, and a Strong Growth Path for its Boston Unit 05/12/11 New York
Page 2 of 3 « previous page · next page »